ClinicalTrials.gg
RecruitingNCT07704255Updated Jul 15, 2026

Study on the Effect of Fecal Microbiota Transplantation on Eradication of Refractory Helicobacter Pylori Infection

A Phase 4 interventional study of transanal fecal bacteria transplant in Helicobacter Pylori Infection, sponsored by Sichuan Provincial People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Sichuan Provincial People's Hospital · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

To determine whether regulating the gut microbiota can contribute to the eradication of refractory H. pylori infection.

02

Conditions studied

  • Helicobacter Pylori Infection

Keywords

  • washed microbiota
03

In context

Lead sponsor

Sichuan Provincial People's Hospital is the lead sponsor of 78 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Ages 18-70
  • 2. Hp infection treatment failed ≥4 times with guidelines-recommended therapies
  • 3. Patients with early gastric cancer, peptic ulcer, gastric MALT lymphoma, atrophic gastritis and other diseases requiring the eradication of Hp.

Exclusion criteria

Exclusion Criteria:

  • 1. Antibiotics and bismuth were taken within 4 weeks before this treatment; Or had taken PPI, H2 receptor antagonist, P-CAB within 2 weeks prior to treatment;
  • 2. Pregnant or lactating women;
  • 3. Those who are allergic to the drugs used in this test or have ;
  • 4. Participated in other drug trials within 3 months before the treatment of this trial;
  • 5. There are other serious diseases that affect the evaluation of this study at the same time, or they cannot correctly express their own complaints and cannot cooperate;
  • 6. Subjects with dysphagia;
  • 7. Patients with malignant tumors, serious concomitant diseases, severe ulcer bleeding or perforation;
  • 8. Patients judged by the investigator to be unsuitable for clinical trials.
  • 9. Those who do not want to sign the for the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    washed microbiota

    Study on the effect of washed microbiota transplantation on eradication of refractory Helicobacter pylori infection.

    Biological: transanal fecal bacteria transplant

Interventions

  • Biologicaltransanal fecal bacteria transplant

    Received transanal fecal bacteria transplant

06

What researchers measure

Primary outcomes

  1. Whether Hp is successfully eradicated

    The successful eradication of Hp was determined by 13C urea breath test, immunohistochemical staining of Hp and Hp culture.test, immunohistochemical staining of gastric mucosa and Hp culture

    Time frame: 2years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Chen YC, Malfertheiner P, Yu HT, Kuo CL, Chang YY, Meng FT, Wu YX, Hsiao JL, Chen MJ, Lin KP, Wu CY, Lin JT, O'Morain C, Megraud F, Lee WC, El-Omar EM, Wu MS, Liou JM. Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022. Gastroenterology. 2024 Apr;166(4):605-619. doi: 10.1053/j.gastro.2023.12.022. Epub 2024 Jan 2. PubMed 38176660 ↗
  • Kuo CJ, Lee CH, Chang ML, Lin CY, Lin WR, Su MY, Chiu CH, Tseng CN, Wu YS, Chiu CT, Lai CH. Multidrug resistance: The clinical dilemma of refractory Helicobacter pylori infection. J Microbiol Immunol Infect. 2021 Dec;54(6):1184-1187. doi: 10.1016/j.jmii.2021.03.006. Epub 2021 Mar 23. PubMed 33840604 ↗
  • Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B, Nam BH. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. N Engl J Med. 2018 Mar 22;378(12):1085-1095. doi: 10.1056/NEJMoa1708423. PubMed 29562147 ↗
  • Su NY, Shi Q, Mei H, Hu J, Liu YX, Liu HN, Liu HQ, Guo Y, Wang XW, Lan CH. Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis. Helicobacter. 2023 Oct;28(5):e13003. doi: 10.1111/hel.13003. Epub 2023 Aug 10. PubMed 37565458 ↗
  • Shirai N, Sugimoto M, Kodaira C, Nishino M, Ikuma M, Kajimura M, Ohashi K, Ishizaki T, Hishida A, Furuta T. Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur J Clin Pharmacol. 2007 Aug;63(8):743-9. doi: 10.1007/s00228-007-0302-8. Epub 2007 Jun 13. PubMed 17565490 ↗
  • Liu D, Wang J, Xie Y. Refractory Helicobacter pylori infection and the gastric microbiota. Front Cell Infect Microbiol. 2022 Sep 27;12:976710. doi: 10.3389/fcimb.2022.976710. eCollection 2022. PubMed 36237432 ↗
  • Shirzad-Aski H, Besharat S, Kienesberger S, Sohrabi A, Roshandel G, Amiriani T, Norouzi A, Keshtkar A. Association Between Helicobacter pylori Colonization and Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2021 May-Jun 01;55(5):380-392. doi: 10.1097/MCG.0000000000001415. PubMed 32833699 ↗
  • Tepler A, Narula N, Peek RM Jr, Patel A, Edelson C, Colombel JF, Shah SC. Systematic review with meta-analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease. Aliment Pharmacol Ther. 2019 Jul;50(2):121-131. doi: 10.1111/apt.15306. Epub 2019 Jun 5. PubMed 31165513 ↗
  • Ismail HF, Fick P, Zhang J, Lynch RG, Berg DJ. Depletion of neutrophils in IL-10(-/-) mice delays clearance of gastric Helicobacter infection and decreases the Th1 immune response to Helicobacter. J Immunol. 2003 Apr 1;170(7):3782-9. doi: 10.4049/jimmunol.170.7.3782. PubMed 12646644 ↗
  • Ismail HF, Zhang J, Lynch RG, Wang Y, Berg DJ. Role for complement in development of Helicobacter-induced gastritis in interleukin-10-deficient mice. Infect Immun. 2003 Dec;71(12):7140-8. doi: 10.1128/IAI.71.12.7140-7148.2003. PubMed 14638805 ↗
  • Chen W, Shu D, Chadwick VS. Helicobacter pylori infection: mechanism of colonization and functional dyspepsia Reduced colonization of gastric mucosa by Helicobacter pylori in mice deficient in interleukin-10. J Gastroenterol Hepatol. 2001 Apr;16(4):377-83. doi: 10.1046/j.1440-1746.2001.02459.x. PubMed 11354274 ↗
  • Ye ZN, Xia HH, Zhang R, Li L, Wu LH, Liu XJ, Xie WR, He XX. The Efficacy of Washed Microbiota Transplantation on Helicobacter pylori Eradication: A Pilot Study. Gastroenterol Res Pract. 2020 Oct 19;2020:8825189. doi: 10.1155/2020/8825189. eCollection 2020. PubMed 33133183 ↗
  • Brunse A, Martin L, Rasmussen TS, Christensen L, Skovsted Cilieborg M, Wiese M, Khakimov B, Pieper R, Nielsen DS, Sangild PT, Thymann T. Effect of fecal microbiota transplantation route of administration on gut colonization and host response in preterm pigs. ISME J. 2019 Mar;13(3):720-733. doi: 10.1038/s41396-018-0301-z. Epub 2018 Oct 26. PubMed 30367124 ↗
  • de Klerk N, Maudsdotter L, Gebreegziabher H, Saroj SD, Eriksson B, Eriksson OS, Roos S, Linden S, Sjolinder H, Jonsson AB. Lactobacilli Reduce Helicobacter pylori Attachment to Host Gastric Epithelial Cells by Inhibiting Adhesion Gene Expression. Infect Immun. 2016 Apr 22;84(5):1526-1535. doi: 10.1128/IAI.00163-16. Print 2016 May. PubMed 26930708 ↗
  • Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003 Feb 8;361(9356):512-9. doi: 10.1016/S0140-6736(03)12489-0. PubMed 12583961 ↗
  • Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. Diversity of the human intestinal microbial flora. Science. 2005 Jun 10;308(5728):1635-8. doi: 10.1126/science.1110591. Epub 2005 Apr 14. PubMed 15831718 ↗
  • National Institute of Hospital Administration, NHC; Society of Parenteral and Enteral Nutrition, Chinese Medical Association; Intestinal Microecology Cooperative Group, Chinese Society for Parenteral and Enteral Nutrition. [Expert consensus on clinical application management of fecal microbiota transplantation (2022 edition)]. Zhonghua Wei Chang Wai Ke Za Zhi. 2022 Sep 25;25(9):747-756. doi: 10.3760/cma.j.cn441530-20220725-00324. Chinese. PubMed 36117364 ↗
  • Gilca-Blanariu GE, Stefanescu G, Girleanu I, Iqbal T, Segal J, Mullish B, Quraishi MN, Keller J, Molnar T, Megraud F, Dumitrascu D, Manuc M, Iancu LS, Marica C, Gheorghe C, Manzoor S, Trifan A. Romanian National Guideline on Translating Fecal Microbiota Transplantation Applications related to Clostridioides difficile Infections into the Local Clinical Practice. J Gastrointestin Liver Dis. 2021 Mar 13;30(1):147-163. doi: 10.15403/jgld-3297. PubMed 33723543 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Dec 2026, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Jul 15, 2026
StartEst.
Jul 20, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07704255
Lead sponsor
Sichuan Provincial People's Hospital
Responsible party
Gao Caiping (Chief physician, Sichuan Provincial People's Hospital) — Principal investigator
First posted
Jul 15, 2026
Start date
Jul 20, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 15, 2026

Study contacts

Gao Caiping, Doctor
Contact
gaocaip@126.com
17708130286
Xia Yuehan, Master
Contact
694159760@qq.com
13438917607

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion